Jershon Evan Varble, | |
2572 E South Weber Dr Ste 5, South Weber, UT 84405-9550 | |
(801) 479-7045 | |
Not Available |
Full Name | Jershon Evan Varble |
---|---|
Gender | Male |
Speciality | Physical Medicine & Rehabilitation |
Location | 2572 E South Weber Dr Ste 5, South Weber, Utah |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1821736802 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208100000X | Physical Medicine & Rehabilitation | 12775190-8016 (Utah) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jershon Evan Varble, 311 E 1500 N, Harrisville, UT 84404-7727 Ph: (801) 644-5501 | Jershon Evan Varble, 2572 E South Weber Dr Ste 5, South Weber, UT 84405-9550 Ph: (801) 479-7045 |
News Archive
JumpStart Ventures, which invests in and partners with innovative, early-stage companies in Northeast Ohio, announced an investment commitment of $250,000 in drug development company ChanRx. The two-year-old company is developing a pharmaceutical compound to treat atrial fibrillation, a heart condition that affects two million Americans, with 200,000 new cases being diagnosed each year.
Fitch Ratings sees an active year for new drug applications to be registered to U.S. and European drug regulators considering recent updates to the pharmaceutical industry's late-stage R&D programs. According to Fitch's new Global Pharmaceutical R&D Pipeline report, the Fitch-rated pharmaceutical developers listed in the report plan on submitting marketing applications to the U.S. Food & Drug Administration (FDA) or the European Medicines Agency (EMEA) during 2010 for approval of 22 novel drug therapies.
Using sugar molecules researchers from the University of Copenhagen have developed a new vaccine for hay fever that may reduce treatment times and increase the effect of treatments.
Merck KGaA announced today the acquisition of Bangalore Genei (India) Private Ltd. (BGIP) by its wholly owned subsidiary in India, Merck Specialities Private Ltd., from the Sanmar Group. By combining BGIP's activities with Merck's existing bioscience business, Merck will become one of the leading bioscience companies in India.
› Verified 7 days ago